Zhejiang Medicine Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Zhejiang Medicine Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Zhejiang Medicine Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Zhejiang Medicine Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zhejiang Medicine Co Ltd (Zhejiang Medicine) develops, manufactures, and commercializes nutritional supplements and pharmaceutical products. The company's product portfolio consists of animal nutrition, active pharmaceutical ingredients (APIs) and intermediates, antibiotics, and human nutrition products. It offers products such as aroma chemicals like citronellal, citronellol, geraniol, linalyl acetate, tetrahydrolinalool, linalool, ionone beta, and citral, also nutritional supplements including vitamin A, vitamin E, and combination vitamin A and E soft capsules. The company provides its products in large and small volume injections, freeze dried powder injections, tablets, hard and soft capsules, pills, and oral solutions. It has two research and development centers, namely, Shaoxing Research Institute of Pharmaceutical Industry and Shanghai Health Creation Biological Drug Research and Development Center. Zhejiang Medicine is headquartered in Shaoxing, Zhejiang, China.
Headquarters
China
Address
No. 168 Zhiyuanzhong Avenue, Binhai Xincheng, Shaoxing, Zhejiang, 312366
Website
www.zmc.top
Telephone
86 575 85211979
No of Employees
5,417
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600216 (SHA)
Revenue (2024)
$1.2B
-5.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-24.7%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
-20.6%
(2024 vs 2023)
* As of and is in US$
Zhejiang Medicine Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| API and Intermediate | ZMC |
| Human Nutrition | LaiYi |
| Animal Nutrition | NovoCodex |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Plans/Strategy | In October, the company's subsidiary Changbei Biotechnology announced its plans to invest CNY1.7 billion in the Zhejiang Medicine Changbei Biotechnology Construction Project. |
| 2024 | New Products/Services | In April, the company announced the launch of continuous aseptic spray‑drying process. |
| 2017 | Ownership Changes | In August, the company's 37.9% stake was acquired by Future Industry Investment Fund valued US$89 million. |
Competitor Comparison
| Key Parameters | Zhejiang Medicine Co Ltd | Sinopharm Group Co Ltd | China Meheco Group Co Ltd | Zhejiang NHU Co Ltd | North China Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shaoxing | Shanghai | Beijing | Shaoxing | Shijiazhuang |
| State/Province | Zhejiang | Shanghai | Beijing | Zhejiang | Hebei |
| No. of Employees | 5,417 | 94,910 | 7,949 | 11,508 | 9,972 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Qirong | Chief Financial Officer | Senior Management | 2021 | 37 |
| Chunbo Li | Chairman | Executive Board | - | - |
| Liu Zhong | Vice Chairman | Executive Board | 2025 | 57 |
| Wang Hongwei | Director; President | Executive Board | 2018 | 56 |
| Xing Hai | Director; Deputy Secretary-Party Committee | Executive Board | 2025 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer